CING news

Latest 3 stories · newest Jun 16, 2026

CING

Cingulate receives first company-owned U.S. patent for ADHD drug CTx-1301

Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 for its lead ADHD asset CTx-1301, protecting the drug's formulation and method of use through December 2042. The patent strengthens the company's intellectual property portfolio as it advances toward potential commercialization of i…

Regulatory Jun 16, 2026 sentiment +0.75 SEC filing ↗

CING

Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday

News Jun 9, 2026 sentiment 0.00 Source: benzinga.com ↗

CING

FDA issues Complete Response Letter for CTx-1301; no safety or efficacy concerns

Cingulate received an FDA Complete Response Letter for its ADHD drug CTx-1301 with only Chemistry, Manufacturing and Controls (CMC) information requests and no clinical safety or efficacy concerns identified. The company has $30 million in cash and plans to promptly resubmit with the requested infor…

Regulatory Jun 2, 2026 sentiment +0.65 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CING feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CING/newsSTART FREE